Identification of a robust signature for clinical outcomes and immunotherapy response in gastric cancer: based on N6-methyladenosine related long noncoding RNAs.

ABSTRACT:

Background

Gastric cancer (GC) is a globally prevalent cancer, ranking fifth for incidence and fourth for mortality worldwide. The N6-methyladenosine (m⁶A) related long noncoding RNAs (lncRNAs) were widely investigated in recent studies. Nevertheless, the underlying prognostic implication and tumor immune mechanism of m⁶A-related lncRNA in GC remain unknown.

Methods

We systematically assessed the m⁶A modification expression of 407 GC clinical samples based on 23 m⁶A regulators and comprehensively associated these genes with lncRNAs. Then, we constructed a m⁶A-related lncRNA prognostic signature (m⁶A-LPS) to evaluate both status and prognosis of the disease. Immune-related mechanisms were explored via dissectin

SUBMITTER: Han T 

PROVIDER: S-EPMC8365962 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature